A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor
NRG Oncology

Protocol Number
GY007

To Learn More Call
201-510-0910